251 related articles for article (PubMed ID: 22041109)
1. Mass balance study of [¹⁴C]eribulin in patients with advanced solid tumors.
Dubbelman AC; Rosing H; Jansen RS; Mergui-Roelvink M; Huitema AD; Koetz B; Lymboura M; Reyderman L; Lopez-Anaya A; Schellens JH; Beijnen JH
Drug Metab Dispos; 2012 Feb; 40(2):313-21. PubMed ID: 22041109
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial.
Morgan RJ; Synold TW; Longmate JA; Quinn DI; Gandara D; Lenz HJ; Ruel C; Xi B; Lewis MD; Colevas AD; Doroshow J; Newman EM
Cancer Chemother Pharmacol; 2015 Nov; 76(5):897-907. PubMed ID: 26362045
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of eribulin mesylate in cancer patients with normal and impaired renal function.
Tan AR; Sarantopoulos J; Lee L; Reyderman L; He Y; Olivo M; Goel S
Cancer Chemother Pharmacol; 2015 Nov; 76(5):1051-61. PubMed ID: 26433580
[TBL] [Abstract][Full Text] [Related]
4. Metabolism of patupilone in patients with advanced solid tumor malignancies.
Kelly KR; Zollinger M; Lozac'h F; Tan E; Mita A; Waldmeier F; Urban P; Anand S; Wang Y; Swart P; Takimoto C; Mita M
Invest New Drugs; 2013 Jun; 31(3):605-15. PubMed ID: 22918719
[TBL] [Abstract][Full Text] [Related]
5. Biotransformation of [
Pusalkar S; Plesescu M; Gupta N; Hanley M; Venkatakrishnan K; Wu JT; Xia C; Zhang X; Chowdhury S
Cancer Chemother Pharmacol; 2018 Nov; 82(5):803-814. PubMed ID: 30128949
[TBL] [Abstract][Full Text] [Related]
6. Assessment of the absorption, metabolism and excretion of [¹⁴C]pasireotide in healthy volunteers using accelerator mass spectrometry.
Lin TH; Hu K; Flarakos J; Sharr-McMahon M; Mangold JB; He H; Wang Y
Cancer Chemother Pharmacol; 2013 Jul; 72(1):181-8. PubMed ID: 23680921
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the Pharmacokinetics and Mass Balance of a Single Oral Dose of Trofinetide in Healthy Male Subjects.
Darwish M; Nunez R; Youakim JM; Robertson P
Clin Drug Investig; 2024 Jan; 44(1):21-33. PubMed ID: 38017349
[TBL] [Abstract][Full Text] [Related]
8. Absorption, distribution, metabolism, and excretion (ADME) of ¹⁴C-sonidegib (LDE225) in healthy volunteers.
Zollinger M; Lozac'h F; Hurh E; Emotte C; Bauly H; Swart P
Cancer Chemother Pharmacol; 2014 Jul; 74(1):63-75. PubMed ID: 24817600
[TBL] [Abstract][Full Text] [Related]
9. Absorption, distribution, metabolism, and excretion of [(14)C]BYL719 (alpelisib) in healthy male volunteers.
James A; Blumenstein L; Glaenzel U; Jin Y; Demailly A; Jakab A; Hansen R; Hazell K; Mehta A; Trandafir L; Swart P
Cancer Chemother Pharmacol; 2015 Oct; 76(4):751-60. PubMed ID: 26254025
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, metabolism and excretion of [(14)C]-lenalidomide following oral administration in healthy male subjects.
Chen N; Wen L; Lau H; Surapaneni S; Kumar G
Cancer Chemother Pharmacol; 2012 Mar; 69(3):789-97. PubMed ID: 22037879
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of absorption, distribution, metabolism, and excretion of [
Liao M; Watkins S; Nash E; Isaacson J; Etter J; Beltman J; Fan R; Shen L; Mutlib A; Kemeny V; Pápai Z; van Tilburg P; Xiao JJ
Invest New Drugs; 2020 Jun; 38(3):765-775. PubMed ID: 31250355
[TBL] [Abstract][Full Text] [Related]
12. A single dose mass balance study of the Hedgehog pathway inhibitor vismodegib (GDC-0449) in humans using accelerator mass spectrometry.
Graham RA; Lum BL; Morrison G; Chang I; Jorga K; Dean B; Shin YG; Yue Q; Mulder T; Malhi V; Xie M; Low JA; Hop CE
Drug Metab Dispos; 2011 Aug; 39(8):1460-7. PubMed ID: 21602311
[TBL] [Abstract][Full Text] [Related]
13. Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer.
Baker SD; Wirth M; Statkevich P; Reidenberg P; Alton K; Sartorius SE; Dugan M; Cutler D; Batra V; Grochow LB; Donehower RC; Rowinsky EK
Clin Cancer Res; 1999 Feb; 5(2):309-17. PubMed ID: 10037179
[TBL] [Abstract][Full Text] [Related]
14. Absorption, metabolism, and excretion of oral ¹⁴C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men.
Scheers E; Leclercq L; de Jong J; Bode N; Bockx M; Laenen A; Cuyckens F; Skee D; Murphy J; Sukbuntherng J; Mannens G
Drug Metab Dispos; 2015 Feb; 43(2):289-97. PubMed ID: 25488930
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment.
Devriese LA; Witteveen PO; Marchetti S; Mergui-Roelvink M; Reyderman L; Wanders J; Jenner A; Edwards G; Beijnen JH; Voest EE; Schellens JH
Cancer Chemother Pharmacol; 2012 Dec; 70(6):823-32. PubMed ID: 23010853
[TBL] [Abstract][Full Text] [Related]
16. A phase I, open-label, mass balance study of [(14)C] dacomitinib (PF-00299804) in healthy male volunteers.
Bello CL; Smith E; Ruiz-Garcia A; Ni G; Alvey C; Loi CM
Cancer Chemother Pharmacol; 2013 Aug; 72(2):379-85. PubMed ID: 23760812
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, metabolism, and routes of excretion of intravenous irofulven in patients with advanced solid tumors.
Paci A; Rezai K; Deroussent A; De Valeriola D; Re M; Weill S; Cvitkovic E; Kahatt C; Shah A; Waters S; Weems G; Vassal G; Lokiec F
Drug Metab Dispos; 2006 Nov; 34(11):1918-26. PubMed ID: 16896064
[TBL] [Abstract][Full Text] [Related]
18. Metabolism and excretion of ropivacaine in humans.
Halldin MM; Bredberg E; Angelin B; Arvidsson T; Askemark Y; Elofsson S; Widman M
Drug Metab Dispos; 1996 Sep; 24(9):962-8. PubMed ID: 8886605
[TBL] [Abstract][Full Text] [Related]
19. Biotransformation Pathways and Metabolite Profiles of Oral [
Pusalkar S; Zhou X; Li Y; Cohen L; Yang JJ; Balani SK; Xia C; Shyu WC; Lu C; Venkatakrishnan K; Chowdhury SK
Drug Metab Dispos; 2020 Mar; 48(3):217-229. PubMed ID: 31911485
[TBL] [Abstract][Full Text] [Related]
20. Elimination pathways of [14C]losoxantrone in four cancer patients.
Joshi AS; Pieniaszek HJ; Vokes EE; Vogelzang NJ; Davidson AF; Richards LE; Chai MF; Finizio M; Ratain MJ
Drug Metab Dispos; 2001 Feb; 29(2):96-9. PubMed ID: 11159796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
